Pituitary ACTH Hypersecretion clinical trials
The registry lists 56 studies for Pituitary ACTH Hypersecretion across more than 10 countries. 14 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-22.
Status
- Completed
- 28
- Recruiting
- 11
- Terminated
- 5
- Active, not recruiting
- 4
- Withdrawn
- 3
- Status unknown
- 2
Phase
- Phase 2
- 16
- Phase 3
- 12
- Phase 4
- 4
- Phase 1
- 2
- Early Phase 1
- 1
Where
- United States
- 36
- France
- 16
- Italy
- 12
- Spain
- 11
- Germany
- 11
- Netherlands
- 9
Who runs them
Novartis Pharmaceuticals (10) · Corcept Therapeutics (4) · Mayo Clinic (3) · RECORDATI GROUP (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · Hospices Civils de Lyon (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · Huashan Hospital (2)
Studies
Recruiting first, then most recently updated. Showing 50 of 56 — search for more.
- An Investigation of Pituitary Tumors and Related Hypothalmic DisordersRecruitingNCT000015951 country
- Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)RecruitingNCT045432531 country
- Long-Term Follow-Up of Survivors of Pediatric Cushing DiseaseRecruitingNCT038319581 country
- PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary TumoursNot yet recruitingNCT07813351Phase 3
- A Trial of Lu AG13909 in Adult Participants With Cushing's DiseaseRecruitingNCT06471829Phase 29 countries
- Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing DiseaseRecruitingNCT05971758Phase 21 country
- Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's DiseaseEnrolling by invitationNCT07108244Not applicable2 countries
- FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing DiseaseRecruitingNCT07460232Early Phase 11 country
- Combination Osilodrostat and Cabergoline in Cushing's DiseaseEnrolling by invitationNCT07603466Phase 41 country
- DDAVP for Pituitary AdenomaRecruitingNCT04569591Not applicable1 country
- Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.RecruitingNCT074636251 country
- Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary TumorsRecruitingNCT073353151 country
- Collecting Information About Treatment Results for Patients With Cushing's SyndromeRecruitingNCT033648031 country
- Multicenter Study of Seliciclib (R-roscovitine) for Cushing DiseaseRecruitingNCT03774446Phase 21 country
- Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeActive, not recruitingNCT03604198Phase 29 countries
- A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's SyndromeActive, not recruitingNCT05804669Phase 1/21 country
- Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015WithdrawnNCT03297892
- Cushing's Disease ComplicationsCompletedNCT025689821 country
- Assessment of Persistent Cognitive Impairment After Cure of Cushing's DiseaseCompletedNCT02603653Not applicable1 country
- Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of HypercorticismsActive, not recruitingNCT039747891 country
- SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's SyndromeCompletedNCT05307328Phase 23 countries
- Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's DiseaseCompletedNCT03346954Not applicable1 country
- A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromeCompletedNCT03697109Phase 311 countries
- Postoperative Thrombosis Prevention in Patients With CDActive, not recruitingNCT04486859Not applicable1 country
- Open-label Treatment in Cushing's SyndromeCompletedNCT03621280Phase 311 countries
- Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s DiseaseWithdrawnNCT04339751Phase 21 country
- Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's DiseaseCompletedNCT0231026911 countries
- Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesCompletedNCT01794793Phase 428 countries
- Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's DiseaseCompletedNCT038178401 country
- Diagnostic Yield of Deep Learning Based Denoising MRI in Cushing's DiseaseTerminatedNCT041219881 country
- Hair Cortisol and Cushing's DiseaseCompletedNCT04201444Not applicable1 country
- Vitamin D Metabolism in Patients With Endocrine DisordersCompletedNCT04844164Phase 11 country
- Treatment of Cushing's Disease With R-roscovitineTerminatedNCT02160730Phase 21 country
- Efficacy and Safety Evaluation of Osilodrostat in Cushing's DiseaseCompletedNCT02697734Phase 314 countries
- Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's DiseaseCompletedNCT00171951Phase 25 countries
- Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 InhibitionCompletedNCT03111810Phase 21 country
- Safety and Efficacy of LCI699 in Cushing's Disease PatientsCompletedNCT01331239Phase 24 countries
- Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's DiseaseCompletedNCT02180217Phase 319 countries
- Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's DiseaseTerminatedNCT01915303Phase 216 countries
- Long-term Cardiovascular Risk in Cured Cushing's PatientsTerminatedNCT008812831 country
- Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)TerminatedNCT00612066Phase 21 country
- Seoul National University Pituitary Disease Cohort StudyStatus unknownNCT034746011 country
- Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyCompletedNCT02060383Phase 412 countries
- Prevention of Metabolic Complications of Glucocorticoid ExcessCompletedNCT01319994Phase 2/31 country
- Rhinological Outcomes in Endonasal Pituitary SurgeryCompletedNCT015043991 country
- An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.CompletedNCT01582061Phase 311 countries
- Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's DiseaseCompletedNCT01374906Phase 320 countries
- Adipokine Profile in Patients With Cushing's Disease on Pasireotide TreatmentCompletedNCT03080181Phase 4
- A Study to Assess SOM230 in Patients With Pituitary Cushing's DiseaseCompletedNCT00088608Phase 21 country
- Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's DiseaseCompletedNCT00434148Phase 318 countries